-+ 0.00%
-+ 0.00%
-+ 0.00%

Rothschild & Co Downgrades Moderna to Sell, Raises Price Target to $81

Benzinga·09/03/2026 11:51:22
Listen to the news
Rothschild & Co analyst Simon Baker downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $40 to $81.